打开APP

收购T-Cell Factory开路,Kite挺进欧洲市场

  1. CAR-T
  2. Kite
  3. T-Cell Factory
  4. 并购
  5. 肿瘤免疫疗法

来源:生物谷 2015-03-18 14:08

最近,Kite医药公司表示将以2100万美元的价格收购了荷兰的小型生物医药公司T-Cell Factory,作为其打入欧洲市场的第一颗钉子。

2015年3月18日讯/生物谷BIOON/--近年来,肿瘤治疗市场上兴起了一股免疫治疗风。而在这一浪潮中涌现出了包括Kite公司、Juno公司等一系列生物医药新贵。凭借着CAR-T疗法,Kite公司在肿瘤治疗领域已经隐然可以和诺华公司等老牌生物医药巨头分庭抗礼。

最近,Kite医药公司又出新招,公司表示将以2100万美元的价格收购了荷兰的小型生物医药公司T-Cell Factory,作为其打入欧洲市场的第一颗钉子。尽管这笔收购案金额并不大,但仍引起了不少分析人士的兴趣。T-Cell Factory公司主要致力于开发T细胞受体技术,这种技术能够刺激人体的免疫系统更高效识别肿瘤细胞表面的抗原并杀灭癌细胞。这一技术无疑能够与Kite公司的现有免疫疗法进行互补。Kite公司官员也表示这一收购案将对公司现有的和美国国家癌症研究中心的合作进行有益补充。

不过,如果认为Kite公司花费上千万美元只是希望获得这个技术,你可能就"too young, too simple"了。根据收购协议,T-Cell Factory将更名为Kite Pharma EU,并将获得T-Cell Factory目前业已与荷兰肿瘤研究中心和其他欧洲研究机构签订的一系列授权协议。以此为契机,Kite公司将能够扩大其在美国海外市场尤其是欧洲市场的影响力和市场份额。公司的研发总裁David Chang也并不避讳这一点,并指出未来一年内公司将凭借这一优势进行一系列大动作。

无疑,2015年将成为Kite公司大展身手的一年。公司将在今年开展关于CAR-T疗法KTE-C19治疗白血病的三项先行实验。Kite公司希望在2017年这种疗法能够获得FDA批准上市。目前公司还有一系列不同肿瘤类型的早期临床研究。

可以说,此次Kite公司的收购行动将点燃欧洲肿瘤免疫疗法市场的战火。让我们拭目以待。(生物谷Bioon.com)

本文系生物谷原创编译整理。欢迎转载!转载请注明来源并附原文链接。更多资讯请下载生物谷资讯APP

【相关会议推荐】

收购T-Cell Factory开路,Kite挺进欧洲市场

2015肿瘤与免疫治疗研讨会将在往届的讨论基础上,增加肿瘤免疫治疗、深度测序、非编码RNA与肿瘤发生、肿瘤干细胞与靶向治疗策略、肿瘤细胞自噬、肿瘤临床多中心与多学科协作研究等内容。我们真诚地邀请活跃在肿瘤基础和转化医学研究第一线的科学和临床工作者与会,见证肿瘤研究领域中的最新突破性理论和技术上的进展,共商开展国际水平的肿瘤转化医学研究的大计。

详细英文报道:

Kite Pharma ($KITE), a leader among companies in the fast-moving field of cancer immunotherapy, is expanding its arsenal of potential treatments and making European landfall with a biotech buyout.

The Santa Monica, CA, company is paying $21 million up front for T-Cell Factory B.V., a private Dutch outfit at work on T cell receptor (TCR) technology through which it rewires patients' immune systems to better combat cancer. T-Cell Factory's platform allows for the discovery and development of TCRs attuned to specific tumors, Kite said, and the Dutch outfit's work will fit in alongside the company's expansive collaboration with the National Cancer Institute in the same field.

Under the deal, T-Cell Factory will be rechristened Kite Pharma EU, and its shareholders are due undisclosed milestone payments tied to clinical, regulatory and sales goals for each resulting TCR project. Through the acquisition, Kite cuts in on some existing licensing agreements with the Netherlands Cancer Institute and other European R&D operations, and the biotech inherits relationships with European clinical manufacturing facilities that will allow it to hit the gas on continental development efforts.

"In addition to expanding our capabilities in TCR, this acquisition is an important first step in our goal of global clinical expansion outside the U.S., applying our leadership and in-house clinical expertise in both CAR and TCR therapies," Kite's head of R&D David Chang said in a statement. "We are pleased with the accelerating momentum of our programs and look forward to additional clinical, operational, and manufacturing progress and accomplishments this year."

Kite has thus made its name in CAR-T therapies, in which scientists remove T cells from a patient's blood and equip them with targeting mechanisms called chimeric antigen receptors (CARs), which seek out and bind to proteins expressed by cancer cells. Like its CAR-T rivals at Juno Therapeutics ($JUNO), Kite is pursuing TCR technology as a complementary approach to immuno-oncology in hopes of building a leading pipeline of such treatments.

Kite has a big year ahead, planning to launch three pivotal studies on the blood cancer-treating KTE-C19 in 2015, and the company has a stated goal of getting the therapy on the market by 2017. Behind its lead asset, Kite has a Phase I CAR-T candidate targeting brain cancer, plus a slew of early-stage TCR treatments for various tumors.

Last month, Kite leased two manufacturing facilities in its native Southern California to manufacture its pipeline therapies, following up on a blockbuster IPO with ambitious plans to contend with Novartis ($NVS), Celgene ($CELG) and a slew of larger competitors in the CAR-T space.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->